V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215465 | 20081575 | 1.52 | 64 | Palliative (P) | 2018-01-25 | 2018-02-01 | IMATINIB | 02 | N | IMATINIB | 101337009 |
| 20215466 | 20081576 | 1.84 | 87 | Curative (C) | null | 2018-04-04 | FLUOROURACIL + MITOMYCIN + RT | null | N | FLUOROURACIL + MITOMYCIN + RT | 101865156 |
| 20215467 | 20081577 | 1.59 | 82.8 | Palliative (P) | 2019-12-07 | 2019-12-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101059272 |
| 20215468 | 20081578 | 1.5 | null | Palliative (P) | 2020-07-11 | 2020-07-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100664374 |
| 20215469 | 20081579 | 1.66 | 51.5 | Palliative (P) | 2020-02-11 | 2020-02-22 | Trial Unspecified | Y | N | TRIAL | 100329451 |
| 20215470 | 20081580 | 1.7 | 61.4 | null | 2019-11-29 | 2019-11-29 | LANREOTIDE | 02 | N | LANREOTIDE | 100850807 |
| 20215471 | 20081581 | 0 | 58.3 | Adjuvant (A) | 2019-05-30 | 2019-06-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101863133 |
| 20215472 | 20081582 | 1.6 | 68.3 | Curative (C) | 2016-03-09 | 2016-03-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100895464 |
| 20215475 | 20081584 | 1.6 | 77.4 | Palliative (P) | 2019-06-18 | 2019-06-18 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101253268 |
| 20215476 | 20081585 | 1.65 | 92 | Adjuvant (A) | 2016-10-30 | 2016-10-31 | IMATINIB | 02 | N | IMATINIB | 100566216 |
| 20215477 | 20081586 | 1.7 | 96.8 | Curative (C) | 2017-06-22 | 2017-06-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101631356 |
| 20215478 | 20081587 | 0 | null | null | 2016-06-20 | 2016-06-29 | LANREOTIDE | 02 | null | LANREOTIDE | 101241010 |
| 20215479 | 20081588 | 1.65 | 80.5 | Palliative (P) | 2017-09-30 | 2017-10-08 | Trial Unspecified | Y | N | TRIAL | 100019003 |
| 20215481 | 20081589 | 1.76 | 0 | Palliative (P) | 2017-01-18 | 2017-01-20 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101381884 |
| 20215483 | 20081590 | 1.81 | 52.3 | Curative (C) | 2018-12-24 | 2019-01-28 | FLUOROURACIL + MITOMYCIN + RT | null | N | FLUOROURACIL + MITOMYCIN + RT | 101002288 |
| 20215484 | 20081591 | null | null | Neo-adjuvant (N) | 2018-01-06 | 2018-01-12 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100994397 |
| 20215485 | 20081592 | 1.47 | 65 | Neo-adjuvant (N) | 2020-02-24 | 2020-02-24 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100226465 |
| 20215486 | 20081593 | null | 92.6 | Palliative (P) | 2017-11-27 | 2017-11-27 | LANREOTIDE | 02 | N | LANREOTIDE | 100334593 |
| 20215487 | 20081594 | 0 | 66.8 | 03 | 2017-09-16 | 2017-09-16 | Imatinib 400mg | 02 | N | IMATINIB | 100760825 |
| 20215489 | 20081596 | null | 98.3 | Palliative (P) | 2020-07-13 | 2020-08-09 | LANREOTIDE | 02 | N | LANREOTIDE | 101145980 |
| 20215490 | 20081597 | 1.7 | 71.5 | Palliative (P) | 2017-03-03 | 2017-03-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101320273 |
| 20215491 | 20081598 | 1.69 | 81.4 | Curative (C) | 2019-06-17 | 2019-06-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100747289 |
| 20215494 | 20081600 | 1.6 | 69.5 | Palliative (P) | 2016-09-01 | 2016-09-15 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101402901 |
| 20215495 | 20081601 | 1.75 | 0 | Palliative (P) | 2022-05-05 | 2022-05-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100624509 |
| 20215496 | 20081602 | 0 | 94.6 | null | 2018-03-02 | 2018-03-03 | Imatinib 400mg | 02 | null | IMATINIB | 100905686 |
| 20215498 | 20081603 | 1.6 | 79.7 | Palliative (P) | 2018-05-20 | 2018-06-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100514765 |
| 20215499 | 20081604 | 1.68 | 72.8 | Palliative (P) | 2018-10-11 | 2018-11-05 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100580590 |
| 20215500 | 20081605 | 0 | 81.6 | 03 | 2017-11-02 | 2017-11-02 | IMATINIB | 02 | N | IMATINIB | 100525041 |
| 20215503 | 20081606 | 1.73 | 80.7 | Palliative (P) | 2019-04-17 | 2019-05-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100773422 |
| 20215505 | 20081607 | null | 65.5 | Palliative (P) | 2016-11-18 | 2016-12-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101360998 |
| 20215506 | 20081608 | 1.6 | 71.4 | Palliative (P) | 2016-09-29 | 2016-10-24 | Trial Unspecified | 01 | N | TRIAL | 100353823 |
| 20215507 | 20081609 | 1.71 | 69.45 | null | 2017-12-17 | 2017-12-21 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101337926 |
| 20215509 | 20081610 | 1.67 | 76.3 | Palliative (P) | 2016-04-03 | 2016-04-04 | Imatinib 400mg | 2 | N | IMATINIB | 100173054 |
| 20215510 | 20081611 | null | 97.5 | Palliative (P) | 2017-06-19 | 2017-06-19 | Trial Unspecified | Y | N | TRIAL | 101340030 |
| 20215512 | 20081612 | 1.72 | 49.4 | Curative (C) | 2018-02-23 | 2018-02-28 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101304083 |
| 20215513 | 20081613 | 1.71 | 82.9 | Palliative (P) | 2018-07-06 | 2018-07-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101683326 |
| 20215515 | 20081614 | 0 | 79 | Palliative (P) | 2022-02-16 | 2022-02-16 | LANREOTIDE | 02 | N | LANREOTIDE | 100210999 |
| 20215517 | 20081615 | 1.79 | 53 | Palliative (P) | null | 2019-07-04 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100155994 |
| 20215518 | 20081616 | 1.75 | 0 | Palliative (P) | 2018-06-15 | 2018-06-27 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101115400 |
| 20215520 | 20081617 | 1.61 | 84 | Palliative (P) | 2018-05-03 | 2018-05-18 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101549143 |
| 20215521 | 20081618 | null | null | Palliative (P) | 2016-06-21 | 2016-06-29 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100810404 |
| 20215522 | 20081619 | 1.83 | 72.5 | Palliative (P) | 2018-06-08 | 2018-06-16 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100341779 |
| 20215523 | 20081620 | 1.82 | 59.7 | Palliative (P) | 2016-08-26 | 2016-08-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101113970 |
| 20215525 | 20081621 | 1.57 | 53.1 | Palliative (P) | 2017-07-21 | 2017-08-18 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101541250 |
| 20215527 | 20081623 | 1.72 | 84.3 | Curative (C) | 2016-06-08 | 2016-06-25 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101021453 |
| 20215528 | 20081624 | 1.63 | 72.65 | Palliative (P) | 2019-05-25 | 2019-06-22 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101016726 |
| 20215533 | 20081627 | 1.63 | 70.5 | Curative (C) | 2016-12-29 | 2016-12-29 | FLUOROURACIL + MITOMYCIN + RT | N | null | FLUOROURACIL + MITOMYCIN + RT | 100072129 |
| 20215534 | 20081628 | 1.63 | 50.1 | Curative (C) | 2019-08-09 | 2019-08-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100896720 |
| 20215539 | 20081631 | 1.78 | 83.1 | Palliative (P) | 2018-12-17 | 2018-12-30 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101700433 |
| 20215540 | 20081632 | 0 | 110 | Palliative (P) | 2017-09-09 | 2017-09-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 101205920 |